Identifying unmet therapeutic domains in schizophrenia patients: The early contributions of wayne fenton from chestnut lodge

Schizophrenia Bulletin

Volumn 33, Issue 5, 2007, Pages 1086-1092

  McGlashan, Thomas H ^b   Carpenter, William T ^a  

^a MARYLAND PSYCHIATRIC RESEARCH CENTER   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cognition; Fenton; Negative symptoms; Psychopathology; Schizophrenia

Indexed keywords

NEUROLEPTIC AGENT;

ARTICLE; COGNITIVE DEFECT; HISTORY; HUMAN; MENTAL HEALTH SERVICE; MENTAL HOSPITAL; METHODOLOGY; PSYCHIATRY; PSYCHOLOGICAL ASPECT; PSYCHOLOGY; PSYCHOTHERAPY; SCHIZOPHRENIA; UNITED STATES;

ANTIPSYCHOTIC AGENTS; COGNITION DISORDERS; HISTORY, 21ST CENTURY; HOSPITALS, PSYCHIATRIC; HUMANS; MARYLAND; NATIONAL INSTITUTE OF MENTAL HEALTH (U.S.); PSYCHIATRY; PSYCHOTHERAPY; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; UNITED STATES;

EID: 38449086528     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbm082     Document Type: Review

References (43)

1. McGlashan TH. The Chestnut Lodge follow-up study: I: Follow-up methodology and study sample. Arch Gen Psychiatry1984;41:573-585. (Pubitemid 14111386)
2. McGlashan TH. The chestnut lodge follow-up study: II: long-term outcome of schizophrenia and the affective disorders. Arch Gen Psychiatry. 1984;41:585-601.
3. Spitzer RL, Endicott J, Robins E. Research Diagnostic Criteria for a Selected Group of Functional Disorders. 3rd ed New York, NY: New York State Department of Mental Hygiene; 1977.
4. Diagnostic and Statistical Manual of Mental Disorders. 3rd ed. Washington, DC: American Psychiatric Association; 1980.
5. Mental disorders: Glossary and Guide to Their Classification in Accordance With the Ninth Revision of the International Classification of Diseases. Geneva, Switzerland: World Health Organization; 1978.
6. Tsuang MT, Winokur G. Criteria for subtyping schizophrenia: clinical differentiation of hebephrenic and paranoid schizophrenia. Arch Gen Psychiatry. 1974;31:43-47.
7. Krawiecka M, Goldberg D, Vaughan M. A standardized psychiatric assessment scale for rating chronic psychotic patients. Acta Psychiatr Scand. 1977;55:299-308. (Pubitemid 8090438)
8. Lewine R, Fogg L, Meltzer H. The development of scales for the assessment of positive and negative symptoms in schizophrenia. Schizophr Bull. 1983;9:368-376.
9. Lindenmayer JP, Kay SR, Opler LA. Positive and negative subtypes in acute schizophrenia. Compr Psychiatry1984;25:455-464. (Pubitemid 14087426)
10. Pogue-Geile MF, Harrow M. Negative and positive symptoms in schizophrenia and depression: a follow-up. Schizophr Bull. 1984;10:371-387.
11. Abrams R, Taylor MA. A rating scale for emotional blunting. Am J Psychiatry1978;135:226-229. (Pubitemid 8275415)
12. Andreasen NC. Negative symptoms in schizophrenia: definitions and reliability. Arch Gen Psychiatry1982;39:784-788. (Pubitemid 12090301)
13. Andreasen NC, Olsen S. Negative vs positive schizophrenia: definition and validation. Arch Gen Psychiatry1982;39: 789-794. (Pubitemid 12090302)
14. Carpenter WT, Heinrichs DS, Wagman AMI. Deficit and non-deficit forms of schizophrenia: the concept. Am J Psychiatry. 1988;145:578-583.
15. Fenton WS, McGlashan TH. Natural history of schizophrenia subtypes I: longitudinal study of paranoid, hebephrenic, and undifferentiated schizophrenia. Arch Gen Psychiatry. 1991;48:969-977.
16. Fenton WS, McGlashan TH. Natural history of schizophrenia subtypes II: positive and negative symptoms and longterm course. Arch Gen Psychiatry. 1991;48:978-986.
17. Carpenter WT, Bartko JJ, Strauss JJ, Hawk AB. Signs and symptoms as predictors of outcome: a report from the International Pilot Study of schizophrenia. Am J Psychiatry1978;135:940-945. (Pubitemid 8378236)
18. Hawk AB, Carpenter WT, Strauss JS. Diagnositic criteria and 5-year outcome in schizophrenia: a report from the International Pilot Study of schizophrenia. Arch Gen Psychiatry. 1975;32:343-356.
19. Strauss JS, Carpenter WT. Characteristic symptoms and outcome in schizophrenia. Arch Gen Psychiatry. 1974;30:117-120.
20. Strauss JS, Carpenter WT. The prediction of outcome in schizophrenia, II: relationships between predictor and outcome variables: a report from the international pilot study of schizophrenia. Arch Gen Psychiatry. 1974;31:37-42.
21. Strauss JS, Carpenter WT Jr, Bartko JJ. The diagnosis and understanding of schizophrenia, part III: speculations on the processes that underlie schizophrenic symptoms and signs. Schizophr Bull. 1974;11:61-69.
22. Fenton WS, McGlashan TH. Antecedents, symptom progression, and long-term outcome of the deficit syndrome in schizophrenia. Am J Psychiatry1994;151:351- 356. (Pubitemid 24081452)
23. McGlashan TH, Fenton WS. Subtype progression and pathophysiologic deterioration in early schizophrenia. Schizophr Bull. 1993;19:71-84. (Pubitemid 23073556)
24. Strauss J, Carpenter WT, Bartko J. The diagnosis and understanding of schizophrenia, III: speculations on the processes that underlie schizophrenic symptoms and signs. Schizophr Bull. 1974;1:61-69.
25. Carpenter WT, Strauss JS. The prediction of outcome in schizophrenia IV: eleven-year follow-up of the Washington IPSS cohort. J Nerv Ment Dis. 1991;179:517-525.
26. Crow TJ. Molecular pathology of schizophrenia: more than one disease process? Br Med J. 1980;280:66-68. (Pubitemid 10199277)
27. Fenton WS, Wyatt RJ, McGlashan TH. Risk factors for spontaneous dyskinesia in schizophrenia. Arch Gen Psychiatry1994;51:643-650. (Pubitemid 24249106)
28. Fenton WS. Prevalence of spontaneous dyskinesia in schizophrenia. J Clin Psychiatry. 2000;61:suppl 410-14.
29. Fenton WS, Blyler CR, Wyatt RJ, Richard J, McGlashan TH. Prevalence of spontaneous dyskinesia in schizophrenic and non-schizophrenic psychiatric patients. Br J Psychiatry1997;171:265-268. (Pubitemid 27400303)
30. Fenton WS, McGlashan TH. Prognostic scale for chronic schizophrenia. Schizophr Bull. 1987;13:277-286. (Pubitemid 18039086)
31. Fenton WS, McGlashan TH. Sustained remission in drug-free schizophrenic patients. Am J Psychiatry1987;144:1306-1309. (Pubitemid 17158771)
32. Fenton WS, McGlashan TH, Victor BJ, Blyler CR. Symptoms, subtype, and suicidality in patients with schizophrenia spectrum disorders. Am J Psychiatry1997;154:199-204. (Pubitemid 27053725)
33. Fenton WS, McGlashan TH. Schizophrenia: individual psychotherapy. Comprehensive Textbook of Psychiatry. 7th ed. 2000; 1217-1231.
34. Hogarty GE. Personal Therapy for Schizophrenia and Related Disorders: A Guide to Individualized Treatment. New York, NY: Guilford Press, 2002.
35. Fenton WS, McGlashan TH. We can talk: individual psychotherapy for schizophrenia. Am J Psychiatry. 1997;154:14931495.
36. Stover EL, Brady L, Marder SR. New paradigms for treatment development. Schizophr Bull. In press.
37. Strauss JS, Bartko JJ, Carpenter WT. New directions in diagnosis: the longitudinal processes of schizophrenia. Am J Psychiatry1981;138:954-958. (Pubitemid 11126520)
38. Carpenter WT Jr. Clinical constructs and therapeutic discovery. Schizophr Res. 2004;72:69-73.
39. Scolnick E. Program to improve cognitive functioning in patients with schizophrenia: reflections. Schizophr Res. 2004;72:75-77. (Pubitemid 39452907)
40. Schizophr Res. 2004; 72:1.
41. Schizophr Bull. 2005; 31:(4).
42. Buchanan RW, Davis M, Goff D, et al. A summary of the FDA-NIMH-MATRICS workshop in clinical trial design for neurocognitive drugs for schizophrenia. Schizophr Bull. 2005;31:5-19. (Pubitemid 41214353)
43. Kirkpatrick B, Fenton WS, Carpenter WT Jr, Marder SR. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull. 2006;32:214-219.